Several hematological adverse effects, as well as development of resistance, have been reported following the treatment with these drugs, so a persistent demand exists for new DNMT inhibitors with low toxicity for the treatment of blood cancers, as well as solid tumors. The gene discussed is DNMT1; the disease is hematopoietic and lymphoid system neoplasm.